SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (1774)4/30/2004 11:03:01 AM
From: tommtn  Read Replies (1) | Respond to of 1870
 
Nice call.



To: bob zagorin who wrote (1774)5/6/2004 11:22:21 AM
From: bob zagorin  Respond to of 1870
 
ISIS conf. call today included comments on genasense in response to analyst question. while making it clear that isis platform is mainly second generation antisense (more targeted, less toxic doses), ISIS said that GNTA trials showed their drug was working, there was an antisense response. they said the toxicity was understandable considering the near max dose mixed with cyt....fwiw. call available today....


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News